Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Top Stories > First foreign COVID vaccines head to China from Germany
    Top Stories

    First foreign COVID vaccines head to China from Germany

    Published by Wanda Rich

    Posted on December 21, 2022

    4 min read

    Last updated: February 2, 2026

    The image features vials labeled 'VACCINE Coronavirus COVID-19' alongside a syringe, set against the Biontech logo. This visual underscores the significance of Germany's first COVID-19 vaccine shipment to China, highlighting the collaboration for vaccine access amid the pandemic.
    Vials of BioNTech COVID-19 vaccine and syringe against Biontech logo backdrop - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:International tradeforeign exchangefinancial servicesInvestment opportunities

    By Thomas Escritt and Alexander Ratz

    BERLIN (Reuters) -Berlin has sent its first batch of BioNTech COVID-19 vaccines to China to be administered initially to German expatriates, a German government spokesperson said on Wednesday, the first foreign coronavirus vaccine to be delivered to the country.

    No details were available on the timing and size of the delivery, although the spokesperson said Berlin is pushing for foreigners other than German nationals, estimated at about 20,000, to be allowed access to the shot if they want it.

    The shipment comes after China agreed to allow German nationals in China to get the shot following a deal during Chancellor Olaf Scholz’s visit in Beijing last month, with the German leader pressing for Beijing to allow the shot to be made freely available to Chinese citizens as well.

    In a letter to be sent to German citizens in mainland China, the government said it would offer basic immunisations and booster shots of vaccines approved for use in the European Union for free to anyone over 12 years of age.

    Family members of other nationalities would not be included. Vaccinations for children under 12 may follow at a later date.

    “We are working on the possibility that besides Germans also other foreigners can be vaccinated with BioNTech,” the spokesperson told journalists in Berlin.

    The shots will be delivered to German companies in China as well as embassy locations and talks are underway with other EU governments about getting them to citizens of other nationalities, a source familiar with the situation said.

    China would need to approve expanding access beyond German nationals, the source said.

    In return, Chinese citizens in Europe can be vaccinated with China’s SinoVac, the spokesperson said.

    The comment comes after a report earlier this month that Germany’s health ministry had granted a permit allowing China’s Sinovac COVID-19 vaccine to be imported to Germany to be given to Chinese citizens in that country.

    The shot has not been approved for use by Europe’s drug regulator, but the World Health Organization has given its green light for its use.

    Beijing has so far insisted on using only domestically produced vaccines, which are not based on the Western mRNA technology but on more traditional technologies.

    The shipment comes amid Beijing dismantling its strict “zero-COVID” regime of lockdowns, which has led to a surge of cases that caught a fragile health system unprepared.

    Experts predict that the country of 1.4 billion people could face more than a million COVID deaths next year.

    Allowing German expats access to a Western shot is a big gesture to Berlin, reflecting Beijing’s effort to strengthen ties with EU’s biggest economy after years of tensions over trade and climate between the two countries.

    Shares in BioNTech rose on news of the shipment, closing 2.3% higher in Frankfurt while Pfizer shares in New York were up 1.25% in late morning New York trade.

    BioNTech was not immediately available to comment on the situation on Wednesday.

    NO WESTERN SHOTS

    China has nine domestically developed COVID vaccines approved for use, more than any other country. But none has been updated to target the highly infectious Omicron variant, as Pfizer-BioNTech and Moderna have for boosters in many developed countries.

    The two shots developed by Pfizer-BioNTech and Moderna are the most widely used around the world.

    Early on in the pandemic, BioNTech struck a deal with Shanghai Fosun Pharmaceutical with a view to supply the shots to greater China.

    While the shots became available in Hong Kong, Macau and Taiwan, the regulatory review for mainland China has not been concluded. BioNTech has said that decision was up to Chinese regulators and has not given a reason for the delay.

    China’s zero-COVID policy and lockdown measures have kept death and infection rates minimal over the past months but caused massive disruptions both domestically and in global trade and supply chains.

    China uses a narrow definition of COVID deaths and reported no new fatalities for Tuesday, even crossing one off its overall tally since the pandemic began, now at 5,241 – a fraction of the tolls of many much less populous countries.

    The National Health Commission said on Tuesday only deaths caused by pneumonia and respiratory failure in patients who had the virus are classified as COVID deaths.

    (Reporting by Thomas Escritt, Alexander Ratz and Christian Kraemer; additional reporting by Danilo Masoni in Milan and Amanda Cooper in London;Writing by Miranda Murray; Editing by Josephine Mason and David Evans)

    Frequently Asked Questions about First foreign COVID vaccines head to China from Germany

    1What is a COVID-19 vaccine?

    A COVID-19 vaccine is a biological preparation that provides acquired immunity against the SARS-CoV-2 virus, which causes COVID-19. Vaccines help prevent illness by stimulating the immune system.

    2What is foreign exchange?

    Foreign exchange, or forex, refers to the global marketplace for trading national currencies against one another. It is essential for international trade and investment.

    3What is a vaccine approval?

    Vaccine approval is the process by which a regulatory authority evaluates and authorizes a vaccine for public use based on its safety and efficacy.

    4What is a booster shot?

    A booster shot is an additional dose of a vaccine given after the initial dose(s) to enhance or restore immunity, particularly when it may have decreased over time.

    More from Top Stories

    Explore more articles in the Top Stories category

    Image for Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Image for Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Image for Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Image for Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Image for Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Image for Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Image for Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Image for PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    Image for A Notable Update for Employee Health Benefits:
    A Notable Update for Employee Health Benefits:
    Image for Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Image for Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Image for ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    View All Top Stories Posts
    Previous Top Stories PostGerman yields steady, spreads tighten after recent repricing
    Next Top Stories PostEngie warns of hit from windfall levies, Belgian nuclear provisions